Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

28 August 2020 (08:00 - 18:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Corina Becker

Bayer AG, Wuppertal (Germany)

56 More presentations in this session

Presentation thumbnail

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Professor Y. Huo (Beijing, CN)

Abstract Slides

Presentation thumbnail

Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics

Doctor S. Frechen (Leverkusen, DE)

Abstract Slides

Presentation thumbnail

Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study

Doctor C. Ballantyne (Houston, US)

Abstract Slides

Presentation thumbnail

The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population

Doctor D. Radenkovic (Greater London, GB)

Abstract Slides

Presentation thumbnail

Adherence to high-intensity statin therapy after acute coronary syndrome and its impact on patient outcome

Doctor P. Sulzgruber (Krems an der Donau, AT)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and Pharmacotherapy ePosters

The Event

ESC Congress 2020

28 August 2020 08:00 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

ESC TV Today

Episode 7: Coronary spasm - Sex differences in heart failure

Congress Session

Challenges in hypertension management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources